THURSDAY, OCTOBER 20

6:00 p.m.-7:00 p.m.  Opening Keynote Address  
Salons EF  

6:00 p.m.-7:00 p.m.  Title to be announced  
Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA  

7:00 p.m.-8:30 p.m.  Opening Reception  
Back Bay  

FRIDAY, OCTOBER 21

7:30 a.m.-8:30 a.m.  Breakfast and Mentoring Roundtables  
Back Bay  

8:30 a.m.-10:30 a.m.  Session 1: Controlling Inflammation in the Tumor Microenvironment  
Salons EF  

Session Chairperson: Laurie H. Glimcher, Dana-Farber Cancer Institute, Boston, MA  

8:30 a.m.-9:00 a.m.  Functional role of endogenous retroviruses in cancer immunity  
Reiner Strick, University-Clinic Erlangen, Erlangen, Germany  

9:00 a.m.-9:30 a.m.  Anti-tumor T cells: You are what you eat  
Susan M. Kaech, Yale University School of Medicine, New Haven, CT  

9:30 a.m.-10:00 a.m.  Stressed out: A novel approach to cancer immunotherapy  
Laurie H. Glimcher  

10:00 a.m.-10:15 a.m.  Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy*  
Stephen Mok, The University of Texas MD Anderson Cancer Center, Houston, TX  

10:15 a.m.-10:30 a.m.  Antigen delivery targeting tumor-infiltrating macrophages leads to eradication of tumor highly resistant to immune checkpoint inhibitors*  
Daisuke Muraoka, University of Shizuoka, Shizuoka, Japan  

10:30 a.m.-11:00 a.m.  Break  
Salons EF Foyer  

*Short talk from proffered abstract
CONFERENCE PROGRAM

11:00 a.m.-1:00 p.m.  Session 2: Key Immuno-Modulatory Cell Subsets
Salons EF

Session Chairperson: Miriam Merad, Mount Sinai Icahn School of Medicine, New York, NY

11:00 a.m.-11:30 a.m.  Innate lymphoid cells regulate the functional properties of tumor infiltrating T cells
Pamela S. Ohashi, Princess Margaret Cancer Centre, Toronto, ON, Canada

11:30 a.m.-12:00 p.m.  Role of TCR specificity in regulatory T cell selection
Chyi-Song Hsieh, Washington University, St. Louis, MO

12:00 p.m.-12:30 p.m.  Myeloid cell contribution to tumor inflammation
Miriam Merad

12:30 p.m.-12:45 p.m.  Prophylactic nodal irradiation abrogates the synergy of tumor radiotherapy and immune checkpoint blockade*
Ariel E. Marciscano, Johns Hopkins University School of Medicine, Baltimore, MD

12:45 p.m.-1:00 p.m.  Targeting regulatory T cells via LAP promotes anti-tumor immunity by decreasing CD103+CD8+ T cells*
Galina Gabriely, Harvard Medical School, Boston, MA

1:00 p.m.-3:00 p.m.  Lunch on own/Free time

3:00 p.m.-5:15 p.m.  Session 3: Immunomodulation
Salons EF

Session Chairperson: Arlene H. Sharpe, Harvard Medical School, Boston, MA

3:00 p.m.-3:30 p.m.  Immune checkpoint blockade in cancer therapies: New insights, opportunities, and prospects for cures
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m.-4:00 p.m.  Title to be announced
Arlene H. Sharpe

4:00 p.m.-4:30 p.m.  The interferon receptor pathway's role in response and resistance to PD-1 blockade
Antoni Ribas, UCLA Medical Center, Los Angeles, CA

4:30 p.m.-4:45 p.m.  Combinatorial proteomic analysis of the receptor programmed cell death-1 uncovers new checkpoint modulators*
Michael Peled, New York University School of Medicine, New York, NY

4:45 p.m.-5:00 p.m.  A LAG-3/PD-L1 bispecific antibody inhibits tumour growth in two syngeneic colon carcinoma models*
Katy Everett, F-star Biotechnology Ltd., Cambridge, United Kingdom
(Not eligible for CME)

5:00 p.m.-5:15 p.m.  Use of a novel mouse model to investigate immune related adverse events arising from immunotherapies*
Stephen J. Blake, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

5:15 p.m.-7:45 p.m.  Poster Session A and Reception
Back Bay

*Short talk from proffered abstract

12  TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
SATURDAY, OCTOBER 22

7:30 a.m.-8:30 a.m.  Breakfast and Mentoring Roundtables
Back Bay

8:30 a.m.-10:30 a.m.  Session 4: New CARs
Salons EF

Session Chairperson: Marcela V. Maus, Massachusetts General Hospital, Charlestown, MA

8:30 a.m.-9:00 a.m.  Adapting CARs for solid tumors
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

9:00 a.m.-9:30 a.m.  Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy
Yvonne Y. Chen, University of California, Los Angeles, CA

9:30 a.m.-10:00 a.m.  CAR-T cells for solid tumors: What have we learned so far?
Marcela V. Maus

10:00 a.m.-10:15 a.m.  Armored CAR T cells genetically modified to secrete IL-12 show enhanced efficacy and overcome a hostile tumor microenvironment in mouse ovarian peritoneal carcinomatosis*
Oladapo Yeku, Memorial Sloan Kettering Cancer Center, New York, NY

10:15 a.m.-10:30 a.m.  A novel chimeric antigen receptor containing JAK-STAT signaling domains mediates superior antitumor effects*
Yuki Kagoya, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

10:30 a.m.-11:00 a.m.  Break
Salons EF Foyer

11:00 a.m.-12:45 p.m.  Session 5: Structural Biology and Biomolecular Engineering of Immune Responses to Cancer
Salons EF

Session Chairperson: Darrell J. Irvine, Koch Institute for Integrative Cancer Research, Cambridge, MA

11:00 a.m.-11:30 a.m.  Title to be announced
Wendell Lim, University of California, San Francisco, CA

11:30 a.m.-12:00 p.m.  Engineering combination immunotherapy agents for synergistic innate and adaptive immune attack on solid tumors
Darrell J. Irvine

12:00 p.m.-12:30 p.m.  Synergistic innate and adaptive immunotherapy
K. Dane Wittrup, Massachusetts Institute of Technology, Cambridge, MA

12:30 p.m.-12:45 p.m.  Enhancing the efficacy of T cell-based immunotherapies using miR-155 engineered tumor-specific CD8+ T cells*
Yun Ji, National Cancer Institute, Bethesda, MD

*Short talk from proffered abstract
CONFERENCE PROGRAM

12:45 p.m.-2:15 p.m.  Lunch on own/Free time

2:15 p.m.-4:00 p.m.  Session 6: Single-Cell Immune Analyses
Salons EF

Session Chairperson: Aviv Regev, Massachusetts Institute of Technology, Cambridge, MA

2:15 p.m.-2:45 p.m.  Technologies for personalizing immunotherapies
James R. Heath, California Institute of Technology, Pasadena, CA

2:45 p.m.-3:15 p.m.  Title to be announced
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA

3:15 p.m.-3:45 p.m.  Title to be announced
Aviv Regev

3:45 p.m.-4:00 p.m.  Dissecting mechanisms of PD-1 blockade with single-cell RNA-sequencing*
Brian C. Miller, Dana Farber Cancer Institute, Boston, MA

4:00 p.m.-4:15 p.m.  Break
Salons EF Foyer

4:15 p.m.-6:00 p.m.  Session 7: Imaging and Cancer Immunology
Salons EF

Session Chairperson: Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA

4:15 p.m.-4:45 p.m.  PET imaging of the immune system using new nucleoside analog probes
Caius G. Radu, University of California, Los Angeles, CA

4:45 p.m.-5:15 p.m.  Profiling immune cell subsets and immune responses in vivo using immunoPET
Anna M. Wu

5:15 p.m.-5:45 p.m.  Single domain antibody fragments as a platform for imaging and therapy
Hidde L. Ploegh, MIT Whitehead Institute for Biomedical Research, Cambridge, MA

5:45 p.m.-6:00 p.m.  PET imaging of the PD-1/PD-L1 checkpoint in naive and radioimmunotherapy-treated tumor-bearing mice*
Gabriele Niedermann, University Clinics Freiburg, Freiburg, Germany

6:00 p.m.-8:45 p.m.  Poster Session B and Reception
Back Bay

*Short talk from proffered abstract
SUNDAY, OCTOBER 23

7:30 a.m.-8:30 a.m.  Breakfast
Back Bay

8:30 a.m.-9:30 a.m.  Keynote Address
Salons EF
8:30 a.m.-9:30 a.m.  Personalizing cancer immunotherapy
Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO

9:30 a.m.-10:00 a.m.  Break
Salons EF Foyer

10:00 a.m.-12:15 p.m.  Session 8: Genomics in Immuno-Oncology
Salons EF
Session Chairperson: Nir Hacohen, The Broad Institute, Massachusetts General Hospital, Charlestown, MA
10:00 a.m.-10:30 a.m.  T cell recognition and tumor resistance in human cancer
Ton Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands
10:30 a.m.-11:00 a.m.  Drivers and resistors of tumor immunity
Nir Hacohen
11:00 a.m.-11:30 a.m.  Genomic correlates of response and resistance to immune checkpoint blockade
Eliezer M. Van Allen, Harvard Medical School, Boston, MA
11:30 a.m.-12:00 p.m.  T-cell transfer therapy targeting somatic mutations in human gastrointestinal cancers
Eric Tran, National Cancer Institute, National Institutes of Health, Bethesda, MD
12:00 p.m.-12:15 p.m.  Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth*
Giovanni Germano, Candiolo Cancer Institute, Candiolo, Italy

12:15 p.m.  Closing Remarks and Departure
Salons EF

*Short talk from proffered abstract